Hubei Biocause Heilen Pharmaceutical Co., Ltd. (301211.SZ)

18.13 -0.53 (-2.84%) At close: 03:04PM CST

Hubei Biocause Heilen Pharmaceutical Co., Ltd.

No. 122 Yangwan Road
Duodao District Jingmen High-tech Zone
Jingmen 448000
China
86 72 4222 3339
https://www.biocause.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 1,012

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Qun Liang	General Manager	N/A	N/A	1971
Mr. Ting Hao Yi	Financial Director	N/A	N/A	1973
Mr. Jian Gao	Board Secretary	N/A	N/A	1977
Mr. Zhenghua Huang	Deputy General Manager	N/A	N/A	1972

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CNY.

Description

Hubei Biocause Heilen Pharmaceutical Co., Ltd. engages in the pharmaceutical, chemical, and new energy fuel businesses in China and internationally. The company provides APIs and intermediates, and formulations; and dimethyl ether gas and a-chloropropionyl chloride chemical products. It is also involved in the contract research, manufacture, and production of APIs, intermediates, and formulations, including tablets, granules, capsules, etc. The company was founded in 1995 and is based in Jingmen, China.

Corporate governance

Hubei Biocause Heilen Pharmaceutical Co., Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.